 |
市場調查報告書
馬來西亞的醫藥品、醫療產業(季度更新報告)Malaysia Pharmaceuticals & Healthcare Q4 2018 |
||||||
| 出版商 | BMI Research | 商品編碼 | 179529 | ||||
| 出版日期 | 內容資訊 | 英文 71 Pages 商品交期: 最快1-2個工作天內 |
|||||
| 價格 |
|
||||||
| 馬來西亞的醫藥品、醫療產業(季度更新報告) Malaysia Pharmaceuticals & Healthcare Q4 2018 | ||
| 出版日期: 2018年09月04日 | 內容資訊: 英文 71 Pages |
|
馬來西亞的醫藥品、醫療產業持續大幅成長，政府對醫療領域的預算擴大，加上人口的增加及疾病的負擔等要素促進醫療需求，今後前景明亮。還有多年的談判結束，預期TPP協定簽訂對該國市場，尤其是跨國公司對專利藥的關注高漲。
本報告提供馬來西亞的製藥、醫療產業結構和最新趨勢相關分析，今後10年的產業規模的動向估計，產業課題(風險)和未來商機(利潤)相關評估，政府的政策、規定，宏觀經濟環境，主要企業簡介等資訊彙整，為您概述為以下內容。
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
The Malaysian pharmaceutical market will benefit from a higher expenditure on healthcare, with the government announcing that it aims to increase its annual budget allocation to the healthcare sector as part of its ongoing effort to improve the health and well-being of the population. Furthermore, we expect the removal of the 6% goods and service tax (GST) will reduce the price of medicines not previously included on the zero-rating list, providing a short-term boost to drug spending in Malaysia. Concerns over the high prices of pharmaceuticals will remain a key theme in Malaysia in the long-term. As such, the Malaysian government will continue to intervene and establish pharmaceutical price controls to increase the population's access to affordable medicines.
